China BioPharma Corp (fka CHBO)

[clearcoated]

Proteonomix, Inc. (PROT) Announces Receipt of First Order for Purchase of Proteoderm's Stem Cell Derived Cosmeceutical Skin Care Product

MOUNTAINSIDE, NJ -- (Marketwire) -- 05/19/09 -- Proteonomix, Inc. (PINKSHEETS: PROT) announced today that its subsidiary, Proteoderm, Inc., has received its first international order for its stem cell derived cosmeceutical kits. China Biopharma, Inc. and Sinoquest Investment Limited, both based in China, have ordered $1 million worth of kits. The order was received pursuant to an exclusive marketing and distribution agreement entered into with the two companies in January 2009.

Pursuant to the purchase order, once Proteonomix confirms its ability to fill orders for five times the quantity of the first order, the purchasers will establish a letter of credit in favor of Proteonomix at an international bank with offices in the United States to be designated by the purchasers. Proteoderm will then manufacture the kits in bulk for shipment to an international cargo facility at a U.S. airport designated by the purchasers.

Michael Cohen, President of Proteonomix and Proteoderm, said, "We could not have asked for a clearer confirmation of the extent of the present and future market for the Proteoderm cosmeceutical, as well as the value of our agreement with China Biopharma and Sinoquest."

Peter Wang, President of China Biopharma and Sinoquest, said that he is excited about this first order and that his companies have already begun the process of preparing the packaging, advertising and marketing of the kits. "We have complete confidence that Proteoderm will fill this order on a timely basis, and that additional orders will soon follow. We have tested the anti-aging properties of the Proteoderm kit and its quality and performance is far superior to anything else we've seen. We are pleased to play a major role by being the first to bring this fine product to market."

The Proteoderm kit contains five carefully matched cosmeceutical products, three of which contain Proteoderm's proprietary, patent-pending natural matrix of bioactive proteins called Matrix NC-138(TM), for use in anti-aging skin care. The products have been shown to enhance the stimulation of collagen and glandular production, leading to a reduction in lines and wrinkles.

Fulfillment of this order is expected in July 2009.

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging cosmetics. For more information, please visit www.proteonomix.com or www.proteoderm.com and www.pinksheets.com.

"Safe Harbor Statement."

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. These statements, which address the Company's financial or business outlook, apply only as of the date the information was issued. Anticipated financial results may not occur.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Michael Cohen
President, Proteonomix, Inc.
Phone: [phone]
Email Contact

http://in.sys-con.com/node/970091

CHBO